Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JEFFREY E LEE and JEAN NICOLAS VAUTHEY.
JEFFREY E LEE
Connection Strength
0.875
JEAN NICOLAS VAUTHEY
  1. Reoperative surgery: a critical risk factor for complications inadequately captured by operative reporting and coding of lysis of adhesions. J Am Coll Surg. 2014 Jul; 219(1):143-50.
    View in: PubMed
    Score: 0.123
  2. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. J Am Coll Surg. 2014 Jul; 219(1):111-20.
    View in: PubMed
    Score: 0.031
  3. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
    View in: PubMed
    Score: 0.030
  4. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014 Jan; 18(1):146-55; discussion 155-6.
    View in: PubMed
    Score: 0.030
  5. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014 Feb; 18(2):269-78; discussion 278.
    View in: PubMed
    Score: 0.030
  6. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May; 16(5):430-8.
    View in: PubMed
    Score: 0.030
  7. Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients. HPB (Oxford). 2014 Apr; 16(4):373-83.
    View in: PubMed
    Score: 0.029
  8. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg. 2012 Nov; 16(11):2056-63.
    View in: PubMed
    Score: 0.027
  9. Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors. Ann Surg Oncol. 2012 Dec; 19(13):4078-84.
    View in: PubMed
    Score: 0.027
  10. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012 Sep; 16(9):1696-704.
    View in: PubMed
    Score: 0.027
  11. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg. 2012 Jul; 215(1):41-51; discussion 51-2.
    View in: PubMed
    Score: 0.027
  12. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012 Dec 01; 118(23):5749-56.
    View in: PubMed
    Score: 0.027
  13. Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. HPB (Oxford). 2012 Aug; 14(8):506-13.
    View in: PubMed
    Score: 0.027
  14. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 2012 Jun; 14(6):365-72.
    View in: PubMed
    Score: 0.027
  15. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012 Jun; 19(6):2045-53.
    View in: PubMed
    Score: 0.026
  16. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Aug 01; 118(15):3801-11.
    View in: PubMed
    Score: 0.026
  17. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012 Jan; 16(1):68-78; discussion 78-9.
    View in: PubMed
    Score: 0.026
  18. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012 Jun 15; 118(12):3182-90.
    View in: PubMed
    Score: 0.026
  19. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Jan 01; 118(1):268-77.
    View in: PubMed
    Score: 0.025
  20. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
    View in: PubMed
    Score: 0.023
  21. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009 Apr; 16(4):836-47.
    View in: PubMed
    Score: 0.022
  22. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3487-95.
    View in: PubMed
    Score: 0.021
  23. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3496-502.
    View in: PubMed
    Score: 0.021
  24. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008 May; 206(5):833-46; discussion 846-8.
    View in: PubMed
    Score: 0.020
  25. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007 Jul; 246(1):52-60.
    View in: PubMed
    Score: 0.019
  26. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg. 2007 Mar; 204(3):347-55.
    View in: PubMed
    Score: 0.019
  27. Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol. 2006 Apr; 13(4):582-94.
    View in: PubMed
    Score: 0.018
  28. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg. 2005 Nov; 9(8):1094-104; discussion 1104-5.
    View in: PubMed
    Score: 0.017
  29. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg. 2005 Jun; 140(6):584-9; discussion 589-91.
    View in: PubMed
    Score: 0.017
  30. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004 Dec; 8(8):935-49; discussion 949-50.
    View in: PubMed
    Score: 0.016
  31. Comment and perspective on Sewnath and colleagues' recent meta-analysis of the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg. 2003 Apr; 237(4):594-5; author reply 595-6.
    View in: PubMed
    Score: 0.014
  32. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg. 2003 Jan; 7(1):118-128.
    View in: PubMed
    Score: 0.014
  33. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002 May 15; 20(10):2537-44.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.